Binx Health is a commercial-stage diagnostics company specializing in decentralized, point-of-care molecular testing. Its core offering is the binx io, an FDA-cleared, CLIA-waived platform that delivers results for chlamydia and gonorrhea in approximately 30 minutes, enabling single-visit 'test and treat' models. The company is actively expanding its commercial footprint through national distribution agreements and strategic partnerships aimed at increasing access in clinics, colleges, and public health programs. Following the 2023 sale of its consumer testing business to imaware, Binx Health appears focused on scaling its point-of-care platform and related professional services.
Sexual HealthInfectious Disease
Technology Platform
binx io: FDA-cleared, CLIA-waived, rapid molecular point-of-care testing platform for single-visit diagnosis. Delivers results for chlamydia and gonorrhea in ~30 minutes.
Funding History
2
Total raised:$95M
Series B$65MNorthpond Ventures
Series A$30MNovartis
Opportunities
The rising global epidemic of STIs, particularly chlamydia and gonorrhea, creates a pressing need for decentralized, rapid testing solutions to enable immediate treatment.
The CLIA-waived status of the binx io platform allows for deployment in a vast network of non-laboratory settings like primary care clinics, urgent care, and college health centers, significantly expanding the accessible market.
Strategic partnerships with public health departments and major distributors provide direct channels to scale rapidly and address health equity gaps.
Risk Factors
Commercial success depends on effective execution of a national sales and support rollout in a highly competitive diagnostics landscape.
The company currently relies heavily on a single product (binx io) for a specific test menu (CT/NG), creating concentration risk.
Rapid technological evolution and potential new entrants in the POC molecular space could threaten its market position if a more advanced or cost-effective platform emerges.
Competitive Landscape
Binx Health competes in the point-of-care molecular diagnostics segment, facing competition from large, diversified diagnostics companies (e.g., Abbott with its ID NOW platform, Roche with cobas Liat) and specialized rivals like Visby Medical, which also offers a rapid PCR device for STIs. Competition is based on test menu, speed, ease of use, cost, reimbursement, and the strength of commercial distribution networks. Binx's CLIA-waived status for a molecular STI test is a key differentiator.
